Nyrada Quarterly Activities Report & Appendix 4C 30 Jun 2022

Highlights:
• Cholesterol-Lowering Program:
– Nyrada’s PCSK9 inhibitor shown to block the early stages of atherosclerosis in a novel human tissue-engineered blood vessel model of atherosclerosis
– Preclinical safety and toxicology studies expected to commence Q3 CY2022
– COVID-related lockdowns in Shanghai delay drug manufacture, Phase I first-in-human study expected to commence 1H CY2023
– European Patent Office grants patent for novel compounds inhibiting PCSK9
• Brain Injury Program:
– Biological target revealed as versatile TRPC ion channels
– NYR-BI02 is a potent TRPC ion channel blocker, limiting excitotoxicity with potential to pursue multiple additional indications
– Preclinical stroke model study results anticipated during Q3 CY2022
– Preclinical safety and toxicology studies expected to commence Q3 CY2022
– Phase I first-in-human study on track to commence in 2H CY2022
• Strong financial position with cash balance of $10.8M
– Sufficient funding for Phase I studies in both lead programs